University of Tokyo Hospital

Running trials

• Recruiting

  AMAZE 10: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People in Japan With Excess Body Weight Lose Weight

  NCT07822061· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

  NCT07351058· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  NCT07351045· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07170150· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

  NCT07177352· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

  NCT06510374· Phase 3· Ferring Pharmaceuticals· Source

• Active, not recruiting

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

  NCT06128629· Phase 3· Intellia Therapeutics· Source

• Not yet recruiting

  WONDER-02 Trial: Plastic Stent vs. Lumen-apposing Metal Stent for Pancreatic Pseudocysts

  NCT06133023· Tokyo University· Source

• Recruiting

  Management and Outcomes of Local Complications of Acute Pancreatitis and Postoperative Pancreatic Fistula

  NCT07862088· Tokyo University· Source

• Active, not recruiting

  A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

  NCT06081894· Phase 3· Cytokinetics· Source

• Recruiting

  ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

  NCT05580562· Phase 3· Jazz Pharmaceuticals· Source

• Recruiting

  Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

  NCT05327894· Phase 3· Princess Maxima Center for Pediatric Oncology· Source

• Recruiting

  Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs

  NCT04613921· European Foundation for Study of Chronic Liver Failure· Source

• Active, not recruiting

  Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

  NCT04822181· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  Japanese Idiopathic Interstitial Pneumonias Registry

  NCT03041623· North East Japan Study Group· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity3 recruiting
• Childhood cancers2 recruiting
• Type 2 diabetes2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Alzheimer disease1 recruiting
• Amyloidosis1 recruiting
• Bladder cancer1 recruiting
• Liver cirrhosis1 recruiting
• Mild cognitive impairment1 recruiting

Closed trials

• Terminated

  A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab

  NCT06241573· Phase 2/3· Boehringer Ingelheim· Source

• Completed

  Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

  NCT05934526· Phase 3· GB002, Inc.· Source

• Completed

  Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

  NCT05819398· Phase 2/3· Boehringer Ingelheim· Source

• Completed

  A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight

  NCT05813925· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension

  NCT05167825· Phase 3· Janssen Pharmaceutical K.K.· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  NCT05523167· Phase 2/3· argenx· Source

• Completed

  An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis

  NCT05214794· Phase 2· Maruho Co., Ltd.· Source

• Completed

  A Study of iPS Cell-derived Cardiomyocyte Spheroids (HS-001) in Patients With Heart Failure (LAPiS Study)

  NCT04945018· Phase 1/2· Heartseed Inc.· Source

• Completed

  A Study of Guselkumab in Participants With Systemic Sclerosis

  NCT04683029· Phase 2· Janssen Pharmaceutical K.K.· Source

• Completed

  A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

  NCT04102098· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

  NCT03914326· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

  NCT03819153· Phase 3· Novo Nordisk A/S· Source

• Completed

  Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

  NCT03867084· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis

  NCT03957681· Phase 3· Kyowa Kirin Co., Ltd.· Source

• Completed

  EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  NCT03594110· Phase 3· Boehringer Ingelheim· Source

• Completed

  Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

  NCT03713593· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.

  NCT03529045· LivaNova· Source

• Completed

  Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III

  NCT02761070· Phase 3· Kyorin University· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Meningioma14 works · 0 trials
• Dilated cardiomyopathy10 works · 0 trials
• Dermatomyositis and polymyositis (myositis)4 works · 1 trial
• Lichen planus3 works · 0 trials